Radix BioSolutions has received a contract from the Food and Drug Administration, Center for Food Safety and Applied Nutrition to validate a testing system designed to simultaneously detect the most common food allergens. More info

Radix BioSolutions has received a two year Phase II SBIR award from the National Institutes of Health to continue its development work on an immunoassay to detect multiple infectious agents associated with hospital acquired infections. More info


The Department of Homeland Security (DHS) Directorate of Science and Technology, Chemical and Biological Defense Division proposes to enter into a sole source award with Radix BioSolutions, Ltd. for the development and validation of a multiplex assay for identifying and differentiating each of the 7 serotypes of botulinum neurotoxin (solicitation number JA08414).


The Food and Drug Administration (FDA) awards Radix BioSolutions, Ltd. a contract for the development of a multiplex assay for food allergens.

The National Institutes of Allergy and Infectious Disease (NIAID) awards Radix a Phase I SBIR contract for the development of a multiplex assay for C. difficile and antibiotic-associated diarrhea.

Radix BioSolutions, Ltd. announces the launch of its Multiplexed Ricin Biothreat Assay, the first interagency-approved Public Health Actionable Assay for toxin detection.

The Center for Disease Control(CDC) announces its intentions to enter a sole source award to Radix BioSolutions, Ltd. for Ricin Components Differentiation Assay Kits.